Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR6 | P51684 | 10/20 | 0.60 |
| ▸ | CXCR2 | P25025 | 10/20 | 0.51 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14895045 | 0.87 | CCR6 (0.61) | CCR6CXCR2CXCR1 | |
| SCHEMBL12263428 | 0.86 | CCR6 (0.45) | CCR6CXCR2CXCR1 | |
| SCHEMBL12575552 | 0.83 | CXCR2 (0.43) | CCR6CXCR2CXCR1 | |
| SCHEMBL24755299 | 0.81 | CCR6 (0.69) | CCR6CXCR2CXCR1 | |
| SCHEMBL12261140 | 0.78 | CXCR2 (0.67) | CCR6CXCR2CXCR1 | |
| SCHEMBL14895291 | 0.77 | CCR6 (0.69) | CCR6 | |
| SCHEMBL20721218 | 0.75 | CCR6 (1.00) | CCR6CXCR2CXCR1 | |
| SCHEMBL20721297 | 0.74 | CCR6 (1.00) | CCR6CXCR2CXCR1 | |
| SCHEMBL12087066 | 0.74 | GAA (0.52) | CCR6CXCR2CXCR1 | |
| SCHEMBL12261179 | 0.73 | CXCR2 (0.59) | CCR6CXCR2CXCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150374708-A1 | DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED PATHOLOGIES | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2015-12-31 | — | — | US | disclosed |
| US-20150374708-A1 | DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED PATHOLOGIES | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2015-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150374708-A1 | DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED PATHOLOGIES | CCL11, CCL2, CCR1 | CCR6 18/4885CXCR2 5/4885CXCR1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.